Tumor Biology

, Volume 37, Issue 4, pp 4767–4776 | Cite as

Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas

  • Takeaki Ishii
  • Kenichi Kohashi
  • Kunio Iura
  • Akira Maekawa
  • Hirofumi Bekki
  • Yuichi Yamada
  • Hidetaka Yamamoto
  • Kazuki Nabeshima
  • Hiroyuki Kawashima
  • Yukihide Iwamoto
  • Yoshinao Oda
Original Article

Abstract

The Akt/mTOR and MAPK pathways play important roles in modulating cellular function in response to extracellular signals, and they are known to be activated in certain kinds of sarcomas. Few investigations have examined these pathways in dedifferentiated liposarcoma (DDLS), in relation to clinicopathological features. Clinicopathological and immunohistochemical analyses were conducted using 99 DDLS specimens. An in vitro study was also conducted to examine the antitumor effects of an mTOR inhibitor and a MEK inhibitor on two DDLS cell lines. The clinicopathological analyses revealed that the AJCC staging was a significant prognostic factor for overall survival and that the tumor size, depth, and location were significant prognostic factors for event-free survival. Phosphorylated Akt (pAkt), pmTOR, pS6RP, p4E-BP1, pMEK, and pERK expressions were positive in 57.4, 52.4, 71.4, 57.1, 84.1, and 50.8 % of the dedifferentiated component of the 63 primary DDLSs. Positive staining for pmTOR was significantly more frequent in the dedifferentiated component than the well-differentiated component. A univariate prognostic analysis revealed that pmTOR expression was associated with poor prognosis in the tumors in the retroperitoneum/ventral body cavity. The mTOR and MEK inhibitors dose-dependently inhibited the cell proliferation of both DDLS cell lines and decreased the expression of downstream pS6RP and pERK, respectively. The combined use of the two inhibitors enhanced antiproliferative activity. In conclusion, the Akt/mTOR and MAPK pathways were activated in DDLS specimens, and the inhibition of these pathways decreased cell proliferation in DDLS cell lines. Our findings suggest that these pathways could be a therapeutic target for patients with DDLS.

Keywords

Dedifferentiated liposarcoma Prognosis Mammalian target of rapamycin Mitogen-activated protein kinase Immunohistochemistry 

Notes

Acknowledgments

This work was supported by JSPS KAKEN Grant Number 25293088. The English used in this article was revised by KN International (http://www.kninter.com). We would like to express our sincere appreciation to Prof. Masao Tanaka, Department of Surgery and Oncology, Prof. Yoshihiko Maehara, Department of Surgery and Science and Prof. Seiji Naito, Department of urology, Graduate School of Medical Sciences, Kyushu University for kind support for our research.

Compliance with ethical standards

Conflicts of interest

None

References

  1. 1.
    Dei Tos J. Dedifferentiated liposarcoma. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. WHO classification of tumours of soft tissue and bone. Lyon: International Agency for Research on Cancer (IRAC); 2013. p. 37–8.Google Scholar
  2. 2.
    Pedeutour F, Forus A, Coindre JM, Berner JM, Nicolo G, Michiels JF, et al. Structure of the supernumerary ring and giant rod chromosomes in adipose tissue tumors. Genes Chromosom Cancer. 1999;24:30–41.CrossRefPubMedGoogle Scholar
  3. 3.
    Mertens F, Fletcher CD, Dal Cin P, De Wever I, Mandahl N, Mitelman F, et al. Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and MorPhology. Genes Chromosom Cancer. 1998;22:16–25.CrossRefPubMedGoogle Scholar
  4. 4.
    Dalal KM, Kattan MW, Antonescu CR, Brennan MF, Singer S. Subtype specific prognostic nomogram for patients with primary liposarcoma of the retroperitoneum, extremity, or trunk. Ann Surg. 2006;244:381–91.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Italiano A, Toulmonde M, Cioffi A, Penel N, Isambert N, Bompas E, et al. Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival. Ann Oncol. 2012;23:1601–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Jones RL, Fisher C, Al-Muderis O, Judson IR. Differential sensitivity of liposarcoma subtypes to chemotherapy. Eur J Cancer. 2005;41:2853–60.CrossRefPubMedGoogle Scholar
  7. 7.
    Coindre JM, Pedeutour F, Aurias A. Well-differentiated and dedifferentiated liposarcomas. Virchows Arch. 2010;456:167–79.CrossRefPubMedGoogle Scholar
  8. 8.
    Linehan DC, Lewis JJ, Leung D, Brennan MF. Influence of biologic factors and anatomic site in completely resected liposarcoma. J Clin Oncol. 2000;18:1637–43.CrossRefPubMedGoogle Scholar
  9. 9.
    Altomare DA, Testa JR. Perturbations of the AKT signaling pathway in human cancer. Oncogene. 2005;24:7455–64.CrossRefPubMedGoogle Scholar
  10. 10.
    Vakiani E, Solit DB. KRAS and BRAF: drug targets and predictive biomarkers. J Pathol. 2011;223:220–30.CrossRefGoogle Scholar
  11. 11.
    Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2013;485:55–61.CrossRefGoogle Scholar
  12. 12.
    Dasari A, Messersmith WA. New strategies in colorectal cancer: biomarkers of response to epidermal growth factor receptor monoclonal antibodies and potential therapeutic targets in phosphoinositide 3-kinase and mitogen-activated protein kinase pathways. Clin Cancer Res. 2010;16:3811–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36:320–8.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Wang C, Cigliano A, Delogu S, Armbruster J, Dombrowski F, Evert M, et al. Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. Cell Cycle. 2013;12:1999–2010.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Dobashi Y, Suzuki S, Sato E, Hamada Y, Yanagawa T, Ooi A. EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors. Mod Pathol. 2009;22:1328–40.CrossRefPubMedGoogle Scholar
  16. 16.
    Dobashi Y, Suzuki S, Sugawara H, Ooi A. Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors. Hum Pathol. 2007;38:914–25.CrossRefPubMedGoogle Scholar
  17. 17.
    Yamada Y, Kohashi K, Fushimi F, Takahashi Y, Setsu N, Endo M, et al. Activation of the Akt-mTOR pathway and receptor tyrosine kinase in patients with solitary fibrous tumors. Cancer. 2014;120:864–76.CrossRefPubMedGoogle Scholar
  18. 18.
    Takahashi Y, Kohashi K, Yamada Y, Endo M, Setsu N, Ishii T, et al. Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas. Hum Pathol. 2014;45:984–93.CrossRefPubMedGoogle Scholar
  19. 19.
    Tomita Y, Morooka T, Hoshida Y, Zhang B, Qiu Y, Nakamichi I, et al. Prognostic significance of activated AKT expression in soft-tissue sarcoma. Clin Cancer Res. 2006;12:3070–7.CrossRefPubMedGoogle Scholar
  20. 20.
    Setsu N, Kohashi K, Fushimi F, Endo M, Yamamoto H, Takahashi Y, et al. Prognostic impact of the activation status of the Akt/mTOR pathway in synovial sarcoma. Cancer. 2013;119:3504–13.CrossRefPubMedGoogle Scholar
  21. 21.
    Endo M, Yamamoto H, Setsu N, Kohashi K, Takahashi Y, Ishii T, et al. Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res. 2013;19:450–61.CrossRefPubMedGoogle Scholar
  22. 22.
    Setsu N, Yamamoto H, Kohashi K, Endo M, Matsuda S, Yokoyama R, et al. The Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomas. Cancer. 2012;118:1637–48.CrossRefPubMedGoogle Scholar
  23. 23.
    Gutierrez A, Snyder EL, Marino-Enriquez A, Zhang YX, Sioletic S, Kozakewich E, et al. Aberrant AKT activation drives well-differentiated liposarcoma. Proc Natl Acad Sci U S A. 2011;108(39):16386–91.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Trojani M, Contesso G, Coindre JM, Rouesse J, Bui NB, de Mascarel A, et al. Soft-tissue sarcomas of adults; study of pathological prognostic variables and definition of a histopathological grading system. Int J Cancer. 1984;33:37–42.CrossRefPubMedGoogle Scholar
  25. 25.
    Pollock RE, Baker LH, Brennan MF, Coombes K, Kattan M, Kneisl JS, et al. Soft tissue sarcoma. In: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual 7th edn. American Joint Committee on Cancer, Springer: Chicago; 2010. pp 291–298.Google Scholar
  26. 26.
    Nishio J, Iwasaki H, Ishiguro M, Ohjimi Y, Fujita C, Ikegami H, et al. Establishment of a novel human dedifferentiated liposarcoma cell line, FU-DDLS-1: conventional and molecular cytogenetic characterization. Int J Oncol. 2003;22:535–42.PubMedGoogle Scholar
  27. 27.
    Ariizumi T, Ogose A, Kawashima H, Hotta T, Li G, Xu Y, et al. Establishment and characterization of a novel dedifferentiated liposarcoma cell line, NDDLS-1. Pathol Int. 2011;61:461–8.CrossRefPubMedGoogle Scholar
  28. 28.
    Jour G, Gullet A, Liu M, Hoch BL. Prognostic relevance of Fédération Nationale des Centres de Lutte Contre le Cancer grade and MDM2 amplification levels in dedifferentiated liposarcoma: a study of 50 cases. Mod Pathol. 2015;28:37–47.CrossRefPubMedGoogle Scholar
  29. 29.
    Gronchi A, Collini P, Miceli R, Valeri B, Renne SL, Dagrada G, et al. Myogenic differentiation and histological grading are major prognostic determinants in retroperitoneal liposarcoma. Am J Surg Pathol. 2015;39:383–93.CrossRefPubMedGoogle Scholar
  30. 30.
    Guo S, Lopez-Marquez H, Fan KC, Choy E, Cote G, Harmon D, et al. Synergistic effects of targeted PI3K signaling inhibition and chemotherapy in liposarcoma. PLoS One. 2014;9:e93996.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Demetri GD, Chwla SP, Ray-Coquard I, Le Cesne A, Staddon AP, Milhem MM, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy. J Clin Oncol. 2013;31:2485–92.CrossRefPubMedGoogle Scholar
  32. 32.
    Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, et al. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest. 2008;118:3051–64.PubMedPubMedCentralGoogle Scholar
  33. 33.
    Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med. 2008;14:1351–6.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D’Amato GZ, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012;30:78–84.CrossRefPubMedGoogle Scholar
  35. 35.
    Li S, Kong Y, Si L, Chi Z, Cui C, Sheng X, et al. Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma. BMC Cancer. 2014;14:376.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Takeaki Ishii
    • 1
  • Kenichi Kohashi
    • 1
  • Kunio Iura
    • 1
  • Akira Maekawa
    • 1
  • Hirofumi Bekki
    • 1
  • Yuichi Yamada
    • 1
  • Hidetaka Yamamoto
    • 1
  • Kazuki Nabeshima
    • 2
  • Hiroyuki Kawashima
    • 3
  • Yukihide Iwamoto
    • 4
  • Yoshinao Oda
    • 1
  1. 1.Department of Anatomic Pathology, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan
  2. 2.Department of PathologyFukuoka University School of Medicine and HospitalFukuokaJapan
  3. 3.Division of Orthopedic SurgeryNiigata University Graduate School of Medical and Dental SciencesNiigataJapan
  4. 4.Department of Orthopaedic Surgery, Graduate School of Medical SciencesKyushu UniversityFukuokaJapan

Personalised recommendations